Read-through approach for stop mutations in Duchenne muscular dystrophy. An update

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Pharmacology

Background:

• Dystrophinopathies, including Duchenne muscular dystrophy (DMD), result from mutations in the DMD gene on the X chromosome.
• Current treatments like corticosteroids manage symptoms and slow disease progression but do not offer a cure.
• There is a critical need for therapies that can restore dystrophin protein function.

Purpose of the Study:

• To review the development and potential of read-through (RT) therapy for Duchenne muscular dystrophy.
• To highlight RT as a promising pharmacological approach to restore dystrophin protein synthesis.
• To explore the translational journey of RT from basic research to clinical application.

Main Methods:

• Non-systematic review of scientific literature.
• Analysis of research steps from yeast models to human applications.
• Focus on read-through strategies targeting nonsense mutations in the DMD gene.

Main Results:

• Read-through therapy has emerged as a viable strategy to counteract premature stop codons caused by nonsense mutations.
• This approach can potentially restore the synthesis of full-length, functional dystrophin protein.
• The development of RT therapy has progressed through various research stages, demonstrating its successful application.

Conclusions:

• Read-through therapy represents a significant advancement in the treatment of Duchenne muscular dystrophy.
• This approach offers the potential to reverse disease course by restoring dystrophin production.
• Further research and clinical translation are paving the way for innovative treatments for dystrophinopathies.